crizanlizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	5365	1690318-25-2

Description:

Molecule	Description
Synonyms: crizanlizumab crizanlizumab-tmca adavkeo SEG101 SelG1 NVP-LXI262	Crizanlizumab-tmca is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands including P-selectin glycoprotein ligand 1. Binding P-selectin on the surface of the activated endothelium and platelets blocks interactions between endothelial cells, platelets, red blood cells, and leukocytes. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

crizanlizumab
crizanlizumab-tmca
adavkeo
SEG101
SelG1
NVP-LXI262

Crizanlizumab-tmca is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands including P-selectin glycoprotein ligand 1. Binding P-selectin on the surface of the activated endothelium and platelets blocks interactions between endothelial cells, platelets, red blood cells, and leukocytes.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
12.50	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Oct. 28, 2020	EMA	NOVARTIS EUROPHARM LIMITED
Nov. 15, 2019	FDA	NOVARTIS PHARMS CORP

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sickle cell anaemia with crisis	416.89	47.16	71	744	5932	63482275
Pain	152.58	47.16	101	714	740527	62747680
Acute chest syndrome	108.75	47.16	17	798	804	63487403
Back pain	92.06	47.16	51	764	264094	63224113
Infusion related reaction	76.19	47.16	44	771	245477	63242730

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sickle cell anaemia with crisis	393.01	59.88	64	406	3989	34952472
Pain	118.64	59.88	56	414	204619	34751842
Back pain	104.42	59.88	44	426	121745	34834716
Infusion related reaction	91.49	59.88	32	438	53025	34903436
Acute chest syndrome	79.03	59.88	13	457	814	34955647
Chest pain	70.61	59.88	34	436	126728	34829733

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sickle cell anaemia with crisis	420.07	46.58	74	903	7848	79735563
Pain	160.71	46.58	101	876	703701	79039710
Acute chest syndrome	140.41	46.58	23	954	1538	79741873
Back pain	135.37	46.58	68	909	304112	79439299
Infusion related reaction	127.97	46.58	60	917	230177	79513234
Chest pain	80.08	46.58	47	930	282257	79461154
Pain in extremity	66.64	46.58	46	931	364492	79378919

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B06AX01	BLOOD AND BLOOD FORMING ORGANS OTHER HEMATOLOGICAL AGENTS OTHER HEMATOLOGICAL AGENTS Other hematological agents
FDA MoA	N0000194031	P-Selectin Blockers
FDA EPC	N0000194032	Selectin Blocker

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Vaso-occlusive crisis in sickle cell disease	indication	769167005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
P-selectin	Adhesion	P16109	LYAM3_HUMAN	INHIBITOR	IC50	5.59		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
CHEMBL4297734	ChEMBL_ID
D11480	KEGG_DRUG
C000614139	MESH_SUPPLEMENTAL_RECORD_UI
10550	IUPHAR_LIGAND_ID
DB15271	DRUGBANK_ID
018193	NDDF
830102002	SNOMEDCT_US
830160007	SNOMEDCT_US
4038967	VANDF
4038968	VANDF
C4524703	UMLSCUI
10316	INN_ID
2262279	RXNORM
37673	MMSL
37674	MMSL
d09436	MMSL
L7451S9126	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ADAKVEO	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0883	INJECTION	10 mg	INTRAVENOUS	BLA	30 sections
ADAKVEO	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0883	INJECTION	10 mg	INTRAVENOUS	BLA	30 sections
ADAKVEO	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0883	INJECTION	10 mg	INTRAVENOUS	BLA	30 sections